Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1831 to 1845 of 7708 results

  1. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development [GID-TA11404] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years TS ID 11959

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Third molars (impacted) - prophylactic removal [ID898]

    In development [GID-TAG525] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Nipocalimab for treating generalised myasthenia gravis TS ID 11958

    Awaiting development [GID-TA11492] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941

    Awaiting development [GID-TA11481] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    Awaiting development [GID-TA10747] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Bipolar disorder: assessment and management (extraordinary review)

    In development [GID-NG10380] Expected publication date: TBC

    NICE guideline
    In development

  8. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    Awaiting development [GID-TA11442] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918

    Awaiting development [GID-TA11429] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. 10395 - Aprocitentan for treating resistant hypertension TS ID 10395

    Awaiting development [GID-TA11459] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902

    Awaiting development [GID-TA11417] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949

    Awaiting development [GID-TA11465] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953

    Awaiting development [GID-TA11469] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 TS ID 11921

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]

    Awaiting development [GID-TA11162] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development